Business UpdateMay 28, 2026, 07:02 AM
NovaBridge to Present at 2026 Jefferies Global Healthcare Conference
AI Summary
NovaBridge Biosciences announced that its senior management team will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The participation will include a company presentation at 3:10 PM ET and one-on-one investor meetings, with a webcast accessible for 90 days. The company also highlighted its pipeline, including givastomig, which is in a global randomized Phase 2 study, and VIS-101, which completed a Phase 2a study and is set to begin a Phase 2b study in H2 2026.
Key Highlights
- NovaBridge management to present at 2026 Jefferies Global Healthcare Conference.
- Presentation and investor meetings scheduled for Thursday, June 4, 2026.
- Presentation time is 3:10 PM ET, with a webcast available for 90 days.
- Givastomig, a bispecific antibody, is being evaluated in a global randomized Phase 2 study.
- VIS-101 completed a randomized, dose-ranging Phase 2a study for wet AMD.
- VIS-101 expects to initiate a dose-determining Phase 2b study in H2 2026.
Price Impact
More from NBP